Biotech stocks falter
After a seven-year bull run, biotech stocks are weakening, MarketWatch.com reported. A Sunday New York Times article highlighted a price increase of the drug used to treat infection that quick jumped to $750 per dose from $13.50, prompting remarks by presidential candidate Hillary Clinton about managing health care costs. The biotech exchange-traded fund could face its largest weekly fall since August 2011, when it dropped more than 13 percent on fears about European debt.
Trending News
